Inhibikase Therapeutics, Inc. IKT

IKT Company Overview

Inhibikase Therapeutics, Inc. is a clinical-stage biopharmaceutical company focused on developing small-molecule kinase inhibitor therapeutics for neurodegenerative and cardiopulmonary diseases. The company operates within the biotechnology and pharmaceutical industries, with research centered on protein kinase signaling pathways that are believed to contribute to disease progression in disorders such as Parkinson’s disease and related neurodegenerative conditions. Its lead development programs have historically focused on Abelson tyrosine kinase (Abl kinase) inhibition as a potential disease-modifying approach.

The company’s primary value drivers are its proprietary drug candidates and associated intellectual property portfolio. IkT-148009 has been a central clinical asset targeting Parkinson’s disease and gastrointestinal manifestations associated with neurodegeneration. Inhibikase was founded in 2008 and later became publicly traded on Nasdaq under the ticker “IKT.” The company evolved from early-stage kinase research into a clinical-stage organization pursuing central nervous system therapies with a focus on oral small-molecule treatments designed to penetrate relevant biological barriers and modulate disease-linked pathways.